Background

Despite the global availability of multiple sclerosis (MS) treatments, accessing and financing them in Southeast Asia (SEA) remains a challenge. This descriptive survey-based study aimed to describe the current state of MS treatment access and local access dynamics within this region

Methods

The survey questionnaire, comprising of 15 closed-ended and five open-ended questions, was developed by three neurologists with expertise in MS and routine MS patient management, or had training in neuroimmunology. Questionnaire development was guided by the recent Atlas of MS and in alignment with the Access to Treatment framework, focusing on MS diagnosis and treatment issues in SEA. Fifteen neurologists experienced in managing MS across the region were identified as key informants for this study.

Results

All fifteen neurologists participated in the survey via email and videoconferencing between January 2020 and February 2023, which included the following countries: Brunei, Cambodia, Indonesia, Malaysia, Myanmar, Lao PDR, Philippines, Singapore, Thailand, Timor-Leste, and Vietnam. All had at least five years of experience in managing MS patients and six had previously completed a neuroimmunology fellowship programme. SEA countries showed disparities in healthcare financing, availability of neurologists, MS treatments, and investigative tools. Access to MS disease-modifying treatments (DMTs) is hindered by high cost, lack of MS specialists, and weak advocacy efforts. On-label DMTs are not listed as essential medicines regionally except for interferon beta1a and teriflunomide in Malaysia. On-label monoclonals are available only in Malaysia, Singapore, and Thailand. Generic on-label DMTs are unavailable due to lack of distributorship and expertise in using them. Off-label DMTs (azathioprine, methotrexate, and rituximab) predominate in most SEA countries. Other challenges include limited access to investigations, education, and knowledge about DMTs among general neurologists, and absence of registries and MS societies. Patient champions, communities, and MS organisations have limited influence on local governments and pharmaceutical companies. Despite its increasing prevalence, there is a lack of concerted priority setting due to MS being perceived as a rare, non-communicable disease.

Conclusion

This study highlights the distinct dynamics, challenges, and research gaps within this region, and provides suggestions to improve MS diagnosis, education, and medicine access.

1. Aderinto, N., Muili, A. O., & Opanike, J. (2023). Navigating the journey of multiple sclerosis management in Africa, overcoming hurdles and harnessing opportunities: A review. Annals of Medicine and Surgery, 85(5), 1730–1735. https://doi.org/10.1097/MS9.0000000000000624

2. Amezcua, L., Rivera, V. M., Vazquez, T. C., Baez, A. S., Bboza, J., & McCauley, J. L. (2021). Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: A review. JAMA Neurology, 78(12), 1515–1524. https://doi.org/10.1001/jamaneurol.2021.3416

3. Atun, R., Berman, P., & Hsiao, W. (2016). Health systems research volume 1: Contextual analysis of the Malaysian health system. Ministry of Health Malaysia.

4. Bigdeli, M., Jacobs, B., Tomson, G., Laing, R., Hogerzeil, H., Lauer, J. A., & Reich, M. R. (2012). Access to medicines from a health system perspective. Health Policy and Planning, 28(7), 692–704. https://doi.org/10.1093/heapol/czs108

5. Chanatittarat, C., Chaikledkaew, U., Prayoonwiwat, N., Thamnisai, A., & Teerawattananon, Y. (2018). Cost-utility analysis of multiple sclerosis treatment in Thailand. International Journal of Technology Assessment in Health Care, 34(6), 584–592. https://doi.org/10.1017/S026646231800061X

6. Filippi, M., Amato, M. P., Centonze, D., Gallo, P., Gasperini, C., Inglese, M., Laroni, A., Manson, J. I., Pozzilli, C., Rossini, P. M., Trojano, M., & Zaffaroni, M. (2022). Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: An expert opinion. Journal of Neurology, 269(10), 5382–5394. https://doi.org/10.1007/s00415-022-11222-z

7. Gilson, L. (Ed.). (2012). Health policy and systems research: A methodology reader. Alliance for Health Policy and Systems Research, World Health Organization. https://apps.who.int/iris/handle/10665/44803

8. Hartung, D. M. (2021). Health economics of disease-modifying therapy for multiple sclerosis in the United States. Therapeutic Advances in Neurological Disorders, 14, Article 1756286420987031. https://doi.org/10.1177/1756286420987031

9. Ignacio, K. H. D., Espiritu, A. I., & Jamora, R. D. G. (2020). The current status and challenges in multiple sclerosis management in the Philippines. Multiple Sclerosis and Related Disorders, 46, Article 102559. https://doi.org/10.1016/j.msard.2020.102559

10. Kapiriri, L., & Martin, D. K. (2010). Successful priority setting in low and middle income countries: A framework for evaluation. Health Care Analysis, 18(2), 129–147. https://doi.org/10.1007/s10728-009-0121-7

11. Laurson-Doube, J., Rijke, N., Costello, K., & Hemmer, B. (2020). Health-care disparities for people with multiple sclerosis. The Lancet Neurology, 19(3), 207–208. https://doi.org/10.1016/S1474-4422(20)30034-1

12. Laurson-Doube, J., Rijke, N., Helme, A., & Rice, C. M. (2021). Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 27(9), 1403–1410. https://doi.org/10.1177/13524585211019623

13. Multiple Sclerosis International Federation. (2020). Atlas of MS (3rd ed.). Proportion of people with MS treated with DMTs. https://www.atlasofms.org/chart/indonesia/disease-modifying-treatments/proportion-of-people-with-ms-treated-with-dmts

14. Multiple Sclerosis International Federation. (2020). Atlas of MS (3rd ed.). Types of DMT used to treat MS. https://www.atlasofms.org/table/indonesia/disease-modifying-treatments/types-of-dmt-used-to-treat-ms

15. Multiple Sclerosis International Federation. (2020). Atlas of MS (3rd ed.). https://www.atlasofms.org

16. Poungvarin, N. (2007). Resources and organization of neurology care in South East Asia. Neurology Asia, 12(1), 41–46.

17. Rannan-Eliya, R. P., Anuranga, C., Manual, A., & Atun, R. (2016). Improving health care coverage, equity, and financial protection through a hybrid system: Malaysia's experience. Health Affairs, 35(5), 838–846. https://doi.org/10.1377/hlthaff.2015.0838

18. Rojas, J. I., Carnero Contentti, E., Abad, P., Aguayo, A., Alonso, R., Bauer, J., ... & LATAM MS Research Group. (2021). Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. Multiple Sclerosis and Related Disorders, 53, Article 103038. https://doi.org/10.1016/j.msard.2021.103038

19. Sengxeu, N., Dufat, H., Boumediene, F., Bourdy, G., Odano, I., & Preux, P. M. (2020). Availability, affordability, and quality of essential antiepileptic drugs in Lao PDR. Epilepsia Open, 5(4), 550–561. https://doi.org/10.1002/epi4.12437

20. Sharma, A., Minh Duc, N. T., Luu Lam Thang, T., Nam, N. H., Ng, S. J., Abbas, K. S., ... & Karbwang, J. (2021). A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). Journal of General Internal Medicine, 36(10), 3179–3187. https://doi.org/10.1007/s11606-021-06737-1

21. Siritho, S., Thavorncharoensap, M., Chanatittarat, C., & Prayoonwiwat, N. (2018). Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand. Multiple Sclerosis and Related Disorders, 24, 151–156. https://doi.org/10.1016/j.msard.2018.06.012

22. Sugiyanto, S., Sabarudin, H. A., & Fatimah, F. (2022). Current situation of magnetic resonance imaging services in Indonesia. Journal of Medical Imaging and Radiation Sciences, 53(4), S52. https://doi.org/10.1016/j.jmir.2022.10.048

23. Tan, K., Yeo, T., Yong, K. P., & Neuroimmunology Study Group. (2021). Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore—Epidemiology and evolution of an emerging subspecialty. Neurology and Clinical Neuroscience, 9(4), 259–265. https://doi.org/10.1111/ncn3.12497

24. The Lancet Neurology. (2019). Essential medicines for patients with multiple sclerosis. The Lancet Neurology, 18(12), 1067. https://doi.org/10.1016/S1474-4422(19)30412-5

25. Tisavipat, N., Jitpratoom, P., Siritho, S., & Prayoonwiwat, N. (2023). The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: A population-based study. Multiple Sclerosis and Related Disorders, 70, Article 104514. https://doi.org/10.1016/j.msard.2023.104514

26. Traicharoenwong, C. (2022). Magnetic Resonance Imaging (MRI) in Thailand, amount 220 machines. Neuro Networks Organization. https://neuronetworks.org/?p=2704

27. Vijayasingham, L., & Viswanathan, S. (2019). A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region. Multiple Sclerosis Journal, 25(1), 130–131. https://doi.org/10.1177/1352458518809176

28. Vijayasingham, L., Jogulu, U., & Allotey, P. (2017). Challenges for accessing and financing high-cost medicines in multipayer systems: Case studies of multiple sclerosis in Malaysia. Critical Public Health, 29(1), 74–83. https://doi.org/10.1080/09581596.2017.1408803

29. Vijayasingham, L., Govender, V., & Witter, S. (2020). Employment based health financing does not support gender equity in universal health coverage. BMJ, 371, Article m3384. https://doi.org/10.1136/bmj.m3384

30. Viswanathan, S., & Wah, L. M. (2019). A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Multiple Sclerosis Journal, 25(11), 1452–1461. https://doi.org/10.1177/1352458518792404

31. Viswanathan, S., Appiwatanakul, M., Nayak, A., & Southeast Asia Regional Therapeutic Plasma Exchange Consortium. (2019). Proceedings of the inaugural strategy meeting for the establishment of a Southeast Asia regional therapeutic plasma exchange consortium for neurological disorders. Therapeutic Apheresis and Dialysis, 23(3), 289–297. https://doi.org/10.1111/1744-9987.12781

32. Wallin, M. T., Culpepper, W. J., Nichols, E., Bhutta, Z. A., Gebrehiwot, T. T., Hay, S. I., ... & GBD 2016 Multiple Sclerosis Collaborators. (2019). Global, regional, and national burden of multiple sclerosis 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(3), 269–285. https://doi.org/10.1016/S1474-4422(18)30447-5

33. World Health Organization Regional Office for South-East Asia. (2017). Improving access to medicines in the South-East Asia Region: Progress, challenges, priorities. World Health Organization.

34. World Health Organization. (2021). Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031. World Health Organization.

35. World Health Organization. (2023). WHO model list of essential medicines - 23rd list, 2023. World Health Organization.

36. Zeineddine, M., Al-Hajje, A., Salameh, P., & MENA MS Research Group. (2023). Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: A regional survey-based study. Multiple Sclerosis and Related Disorders, 79, Article 104961. https://doi.org/10.1016/j.msard.2023.104961